Drug Trial Radar · NCT07930559
Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Oct 8, 2026
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Aponia Laboratories, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel 5%
Conditions
- Acute Pain Due to Trauma
Interventions
S-Ibuprofen Gel 5%Drug
Topical gel containing active ingredient S-ibuprofen
Vehicle Topical GelDrug
Placebo gel matching the active comparator in conposition and appearance without the active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the efficacy of S-ibuprofen gel 5% applied once every 24 hours compared with placebo in patients with acute contusions of the soft tissues following blunt traumaTime frame: 0-24 hours
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Northwest Foot Care - Amanda Westfall McCarty
Bend, Oregon · Recruiting
Northwest Foot Care - Bryan Wilhelm
Bend, Oregon · Recruiting
Northwest Foot Care - Hayden Bush
Bend, Oregon · Recruiting
Dr. med Jürgen Ulrich Schaale-Maas
Bonn, Germany · Recruiting
Orthopädische Praxis-Ebert
Bonn, Germany · Recruiting
Dr. Helmut Pabst
Gilching, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.